{"id":"nct:NCT07905131","kind":"trial","title":"A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer","authors":["Daniel Nussbaum, M.D."],"author_count":1,"year":2026,"published":"2026-10-29","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07905131","source_url":"https://clinicaltrials.gov/study/NCT07905131","archive_url":"https://space-kitty.com/papers/nct:NCT07905131","updated":"2026-10-29","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to assess the safety, feasibility, and recommended dose of navlimetostat (BMS-986504) combined with mFOLFIRINOX before and after surgery in patients with localized pancreatic cancer with MTAP deletion.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"details":{"acronym":"M-POP","status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":18,"sponsor":"Daniel Nussbaum, M.D.","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["DRUG: Navlimetostat","DRUG: mFOLFIRINOX Treatment Regimen"],"start_date":"2027-01-15","start_date_type":"ESTIMATED","primary_completion_date":"2029-06-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}